BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 14, 2025
See today's BioWorld Asia
Home
» Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B
To read the full story,
subscribe
or
sign in
.
Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B
June 3, 2025
By
Tamra Sami
No Comments
In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.
BioWorld Asia
Deals and M&A
Cancer
Antibody-drug conjugate
Asia-Pacific
China
Japan
